Short-term storage conditions of peptides: avoid light, 4
Likewise, cagrilintide currently has the broadest mature clinical database, especially through CagriSema and active-controlled Phase 3 studies
A 20 percent LDL reduction from a weight-loss-oriented triple agonist is therefore a genuinely new observation and helps explain why retatrutide is being developed across cardiovascular, metabolic, and weight-related indications rather than as a pure obesity asset
Individualized decision-making with your physician is essential
The Phase 2 trial used 2mg as the starting dose, and it is the lowest dose in the standard published titration: 2mg, then 4mg, then 8mg, then 12mg, each held for 4 weeks